Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of <scp>UNCOVER</scp>‐3
Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of <scp>UNCOVER</scp>‐3 is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of <scp>UNCOVER</scp>‐3 have?
Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of <scp>UNCOVER</scp>‐3 has 82 citations in the OpenAlex counts ScholarIQ stores.
When was Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of <scp>UNCOVER</scp>‐3 published?
Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of <scp>UNCOVER</scp>‐3 has 2016 year in the ScholarIQ index.
What is the open-access status of Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of <scp>UNCOVER</scp>‐3?
Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of <scp>UNCOVER</scp>‐3 has closed oa status in the ScholarIQ index.
What is the DOI of Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of <scp>UNCOVER</scp>‐3?
The DOI for Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of <scp>UNCOVER</scp>‐3 is on the source record.
What is the PMID of Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of <scp>UNCOVER</scp>‐3?
The PMID for Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of <scp>UNCOVER</scp>‐3 is on the source record.
What is the OpenAlex record for Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of <scp>UNCOVER</scp>‐3?
The OpenAlex for Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of <scp>UNCOVER</scp>‐3 is on the source record.